NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

When we discuss the median for the Top 100, we must recognize that over a decade ago a patient may have started the trial and lived for say 66 months before passing on. That person, in spite of dying perhaps 5 or more years ago is boosting the median until half or more of the top 100 have passed that 66 month mark. Clearly only the living can expand on it, but as long as there are living people with less months in treatment than the median, they have the opportunity to live beyond the current median, and therefore cause it to go up.

When the median for the Top 100 is fixed, i.e. all the living are beyond the median, the length of the tail continues to grow, and it would be easy to look at the Top 50, who's median should still be growing. I don't believe that most FDA Trials speak about Top 100, but it certainly is an impressive figure that can't help but say, something good is happening here.

Gary